U.S. markets closed

Shattuck Labs, Inc. (STTK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
19.25+1.36 (+7.60%)
At close: 4:00PM EDT
19.25 0.00 (0.00%)
After hours: 07:54PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close17.89
Open17.83
Bid19.26 x 1200
Ask24.20 x 1200
Day's Range17.25 - 19.90
52 Week Range17.15 - 60.52
Volume515,264
Avg. Volume151,103
Market Cap810.864M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.82
Earnings DateNov 11, 2021 - Nov 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est48.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Shattuck Labs, Inc.
    Daily – Vickers Top Buyers & Sellers for 08/13/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • GlobeNewswire

    Shattuck Labs Announces Participation in Upcoming September Conferences

    AUSTIN, TX and DURHAM, NC, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in three virtual investor conferences in September 2021. Presentation Details Conference: Citi 16th Annual BioPharma Virtual Conferen

  • GlobeNewswire

    Shattuck Labs Reports Second Quarter 2021 Financial Results and Upcoming Phase 1 Dose Escalation Data for SL-172154 and SL-279252

    – Announced submission of abstracts for the initial Phase 1 dose-escalation data from both SL-172154 in ovarian cancer and SL-279252 in advanced solid tumors for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in November 2021 – – Reported initial safety data from SL-172154 (SIRPα-Fc-CD40L) Phase 1 trial in ovarian cancer suggesting an encouraging early safety profile and ability to dose escalate beyond prior CD40 agonist antibodies – – Announced plans to study SL-1

  • GlobeNewswire

    Shattuck Labs Announces Participation in the BTIG Biotechnology Conference

    AUSTIN, TX and DURHAM, NC, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in the BTIG Biotechnology Conference being held virtually August 9-10, 2021. Presentation DetailsConference: BTIG Biotechnology ConferenceFormat: Fireside